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Abstract
Background and Purpose: The brain-specific astroglial protein GFAP is a blood biomarker candidate indicative of
intracerebral hemorrhage in patients with symptoms suspicious of acute stroke. Comparably little, however, is known about
GFAP release in other neurological disorders. In order to identify potential ‘‘specificity gaps’’ of a future GFAP test used to
diagnose intracerebral hemorrhage, we measured GFAP in the blood of a large and rather unselected collective of patients
with neurological diseases.
Methods: Within a one-year period, we randomly selected in-patients of our university hospital for study inclusion. Patients
with ischemic stroke, transient ischemic attack and intracerebral hemorrhage were excluded. Primary endpoint was the ICD-
10 coded diagnosis reached at discharge. During hospital stay, blood was collected, and GFAP plasma levels were
determined using an advanced prototype immunoassay at Roche Diagnostics.
Results: A total of 331 patients were included, covering a broad spectrum of neurological diseases. GFAP levels were low in
the vast majority of patients, with 98.5% of cases lying below the cut-off that was previously defined for the differentiation
of intracerebral hemorrhage and ischemic stroke. No diagnosis or group of diagnoses was identified that showed
consistently increased GFAP values. No association with age and sex was found.
Conclusion: Most acute and chronic neurological diseases, including typical stroke mimics, are not associated with
detectable GFAP levels in the bloodstream. Our findings underline the hypothesis that rapid astroglial destruction as in
acute intracerebral hemorrhage is mandatory for GFAP increase. A future GFAP blood test applied to identify patients with
intracerebral hemorrhage is likely to have a high specificity.
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Introduction
Recently, the astroglial protein GFAP has been identified as
a potential blood biomarker of intracerebral hemorrhage (ICH) in
patients with symptoms of acute stroke. [1–4] GFAP is released
rapidly in case of an expanding parenchymal bleeding in the brain
leading to immediate cell destruction, whereas it is detected with
delay in case of ischemic stroke (IS), where necrosis and cellular
disintegration do not occur before 6–12 h after symptom onset.
The different kinetics of GFAP release in ICH and IS, respectively,
may allow for an early, sensitive and specific distinction between
the two major entities of stroke, potentially facilitating the triage of
patients and fostering super early implementation of individually
targeted therapies [4].
GFAP is the main intermediary filament of astrocytes, the most
abundant cell type in the human central nervous system (CNS).
[5,6] It plays an essential role in maintaining shape and motility of
astrocytic processes and contributes to white matter architecture,
myelination and blood-brain barrier integrity. GFAP was found to
be highly brain specific, as relevant extracerebral sources of this
protein have not been identified. As a consequence, blood levels of
GFAP in healthy individuals are very low, typically not exceeding
the lower detection limits of the used tests. [4,7,8] Essential for the
release of GFAP from brain tissue into the blood stream is
supposed to be (I) the loss of astrocytic structural integrity due to
necrosis and/or mechanical disruption and (II) disintegration of
the blood-brain barrier. [1] It is not yet clear, however, whether
the upregulation of GFAP following different pathological events
in the CNS, a process commonly known as reactive astrogliosis,
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levels in peripheral blood [9].
Apart from a considerable number of acute stroke patients,
whose GFAP blood levels are reported in the literature, only little
is known about GFAP in patients with other neurological diseases.
GFAP was found elevated in the plasma of patients with
glioblastoma, whereas other intracranial tumors including metas-
tases were not shown to increase GFAP blood levels. [7,10,11]
Furthermore, GFAP blood levels were shown to correlate with
severity and outcome after traumatic brain injury. [12–14]
Sporadically it was reported that patients with neuromyelitis
optica show increased GFAP plasma levels [15].
In view of the potential use of GFAP as a diagnostic marker of
acute ICH, the present investigation aims at providing a cursory
overview of GFAP levels in a broad and rather unselected
spectrum of neurological conditions and diseases, other than
stroke, brain tumor and traumatic brain injury. We will provide
data on individual GFAP levels and discuss the diagnostic value of
GFAP testing in view of potential ‘‘specificity gaps’’.
Methods
Ethics Statement
The study protocol was approved by the ethics committee of the
Goethe-University, Frankfurt am Main, Germany.
Patient Inclusion and Blood Sampling
Within a one-year period (May 2010 to April 2011), three
inpatients of our university hospital were randomly selected on
every working day (Monday to Friday) as potential study
candidates from all patients who had undergone blood withdrawal
for routine laboratory testing in the morning of that day. Patients
below 18 years of age as well as patients diagnosed as having IS,
transient ischemic attack, ICH, traumatic brain injury or brain
tumor were excluded from the analysis (due to the already existing
data from prospective GFAP studies concerning these disorders).
Candidates or legal representatives were informed about the
purpose of the study and written informed consent was obtained.
1 ml of EDTA-plasma was diverted from the blood drawn earlier
that day for routine purposes and transferred into an Eppendorf
tube. Within 60 minutes after blood draw, samples werde
centrifugated at 10,000 g for 4 min, and the supernatant was
immediately frozen and stored at 225uC. To assure specimen
stability, shipment of samples was performed on dry ice in order to
maintain the cool chain. GFAP is known to be stable in whole
blood for several days at 4uC, and freezing and thawing for up to
four cycles was found to not influence GFAP concentrations [8].
Clinical Parameters
Primary endpoint was the final diagnosis reached at hospital
discharge based on all available clinical and laboratory findings,
including brain imaging. Diagnoses were classified according to
ICD-10. In addition, the following clinical data were prospectively
collected: age, sex and comorbidities such as concomitant
neoplastic disease, concomitant cardiovascular disease, arterial
hypertension, and diabetes mellitus.
GFAP Determination
All scientists involved in the GFAP measurements were fully
blinded to clinical data. Determination of the GFAP plasma
concentrations was performed at Roche Diagnostics, Penzberg,
Germany. An electrochemiluminometric immunoassay for the
in vitro quantitative determination of GFAP in human serum and
plasma (ElecsysH GFAP prototype test) was used. [4] In a first step,
biotin- and ruthenium-labelled monoclonal GFAP antibodies were
combined with 50 ml of sample and incubated for 9 min. In the
second step, streptavidin-coated magnetic microparticles were
added, and the mixture was incubated for 9 min. Then, the
reaction mixture was transferred into the measuring cell where the
beads were magnetically captured on an electrode surface.
Unbound label was removed by washing the measuring cell. In
the last step, voltage was applied to the electrode in the presence of
a tri-propylamine (TPA)-containing buffer and the resulting
electrochemiluminescent signal was recorded by a photomultiplier.
The GFAP concentration was calculated from the read-off on
the basis of a standard calibration curve, defined by a set of seven
master calibrators. Since an acknowledged reference method for
GFAP is lacking to this day, the ElecsysH GFAP assay was
standardized by weighing pure human GFAP in an analyte-free
human serum matrix.
Each GFAP measurement was performed in full calibration
mode. The measuring range of the GFAP prototype assay is
between 0.05 and 150 mg/l (defined by the lower detection limit
and the maximum of the master curve). The lower detection limit
of the assay, defined as the lowest measurable GFAP concentration
distinguishable from zero, was calculated as the concentration two
standard deviations above the lowest standard at 0.05 mg/l.
Intraassay precision was determined using 4 individual samples
run in 21 replicates in a single run and found to range between
1.1% and 1.9%. Interassay precision was determined using the
same samples run in duplicates in 10 individually calibrated runs
and ranged between 2.7–4.2%.
In a collective of 132 apparently healthy individuals, GFAP
plasma levels were determined to be 0.0760.11 mg/l using this
assay. The determination procedure was identical to that used in
the BEFAST trial [4].
Statistical Analysis
GFAP data did not follow a normal distribution. Thus, non-
parametric statistics including median/interquartile range were
used for data exploration, but mean6SD values were also
calculated. Correlation analysis was performed using the Spear-
man rank test. Mann-Whitney U test was used to compare
differences between two groups. Differences between all diagnosis
groups were compared by means of the Kruskal-Wallis test and
Dunn’s correction for multiple testing.
Results
A total of 331 patients were included in the study. Mean age was
51618 years, and 54% were female. Patients had a broad
spectrum of discharge diagnoses, basically covering all relevant
fields of neurological diseases (apart from IS, ICH and brain
tumors; see Figure 1). Concerning non-neurological comorbidities,
6% of the patients had a co-existing neoplastic disease, 14% had
a history of cardiovascular diseases, 20% had arterial hypertension
and 11% diabetes mellitus.
Calculated for the entire dataset, the mean GFAP plasma level
was 0.0660.10 mg/l (median 0.00, interquartile range 0.00–0.10,
minimum 0.00, maximum 0.85). 62.5% of GFAP values were
found below the detection limit of the applied GFAP immunoassay
(0.05 mg/l), whereas 98.5% of GFAP values lay below the cut-off
of 0.29 mg/l that was previously identified as a good discriminator
between ICH and IS. GFAP values were found to be unaffected by
gender and evenly distributed between male and female patients.
GFAP levels did not increase with age. No influence was found for
GFAP regarding the above listed comorbidities.
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increased GFAP values, as is the case in acute ICH (see Figure 1;
Kruskal Wallis-test, p=0.190). The three diagnostic groups
displaying the highest GFAP mean values were bacterial
meningitis (0.1860.33 mg/l), subarachnoid hemorrhage
(0.1360.23 mg/l), and status epilepticus (0.1260.11 mg/l). The
three highest individual GFAP values were found in a case of
Parkinson’s disease (0.85 mg/l), in a patient with subarachnoid
hemorrhage (0.71 mg/l), and in a case of bacterial meningitis
(0.67 mg/l).
Discussion
This explorative study is the first to provide plasma levels of the
brain specific astroglial protein GFAP in patients with a broad
spectrum of neurological diseases. Determined by a technically
advanced GFAP prototype immunoassay, [4] we found low to
very low GFAP blood values in the vast majority of patients,
although many of them presumably had persistent neurological
symptoms at the time point of blood draw. Together with recently
published studies in stroke, [2–4] TBI, [12–14] and brain tumors,
[7,10,11] our study provides further insights into the pathophys-
iology of GFAP release in neurological disorders, which is
discussed below in detail. Furthermore, our study was not able
to identify a condition or disease that may constitute a significant
‘‘specificity gap’’ in a GFAP blood test applied to identify ICH in
patients with symptoms of acute stroke [4].
Our data support the assumption that (acute) structural
disintegration of astroglial cells (i.e., mechanical disruption and/
or necrotic cell death) and leakage through the blood brain barrier,
allowing the protein to trespass from the intracellular compart-
ment into the blood stream, [1] is a prerequisite for detectable
GFAP release in peripheral blood. This convincingly explains the
Figure 1. Patients are grouped according to discharge diagnosis (‘‘ICD’’=International Classification of Diseases). ‘‘n’’ depicts the
number of patients per diagnosis. ‘‘n,0.05’’ displays the number of patients per diagnosis with GFAP values below the lower detection limit of the
used immunoassay. The remaining values (those above the lower detection limit) are displayed as individual values in the graph. Individual patients
with increased GFAP values are easy to recognize. Mean GFAP values and standard deviation (SD) are also provided for each diagnosis. The diagnoses
with the three highest mean GFAP values are labelled in red. *=GFAP value of one sample is missing. **=Results of the BE FAST study for
comparison [4].
doi:10.1371/journal.pone.0062101.g001
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after symptom onset in ICH and traumatic brain injury, re-
spectively. In ICH, a strong correlation exists between ICH
volume and GFAP plasma values, further underlining the above-
mentioned ‘‘mechanic’’ hypothesis. [3,4] In the BE FAST trial,
GFAP values of more than 100 mg/l were found in acute ICH
patients with a mean of 29 mg/l, which is vastly higher than even
the patients with the highest GFAP values in the present study. [4]
In traumatic brain injury, the magnitude of GFAP elevation is
strongly correlated to clinical severity and extent of the brain
lesion. Values.7 mg/l were associated with an unfavorable
outcome, while values.15 mg/l were not survived. [12–14] Three
studies in the literature point to increased GFAP levels in plasma
of patients with malignant glioma (glioblastoma) but not in
metastasis, and suggest a potential use of this marker in the
differential diagnosis of patients with newly identified cerebral
mass lesions. [10,11,16] Malignant glioma tend to produce large
amounts of GFAP, and many of them show substantial areas of
necrotic cell death. Furthermore, it is well known that the blood
brain barrier is disintegrated within the tumor. Thus, a gradual
release of GFAP in to the blood stream appears plausible in
glioblastoma, in contrast to other brain tumors such as metastases.
Apart from what was already known (i.e., elevated GFAP values
in ICH, traumatic brain injury, and glioblastoma), we were not
able to identify a disease or a group of diseases in our widespread
explorative study that was consistently associated with increased
blood GFAP levels. However, a few individual values from
different disease categories were found clearly elevated and need
further consideration: One patient had a subarachnoid hemor-
rhage with a concomitant parenchymal bleeding. [17] This
explains the GFAP increase similar to what happens in intracerebral
hemorrhage. All other patients with subarachnoid hemorrhage
(n=8), however, did not show elevated GFAP blood levels,
suggesting that blood that enters the subarachnoid space not
necessarily leads to brain parenchyma destruction. In one other
patient from our series with elevated GFAP due to severe bacterial
meningitis, we assume astroglial destruction caused by a concom-
itant infection of the brain parenchyma itself, which is a frequent
finding in bacterial meningitis, or due to infectious vasculitis with
cerebral ischemia. In contrast, three more patients with bacterial
meningitis and basically all patients with other forms of CNS
infection did not show increased GFAP blood values. Un-
fortunately, we were not able to provide an explanation for the
elevated GFAP value in a patient with Parkinson’s disease. N=13
other Parkinson patients and 10 more patients with movement
disorders did not reveal increased GFAP value. The same was true
for other neurodegenerative diseases, in particular Alzheimer’s
disease. As there was no other concomitant disease that may
explain GFAP release in this patient, we consider this value as
a statistical outlier. It was reported that neuromyelitis optica
(NMO), an autoimmune CNS disease targeting sites of high
aquaporin-4 density in the spinal cord and the optic nerve, is
associated with a marked loss of astrocytes. Increased GFAP levels
were described in NMO patients, and it was suggested that this
marker might help to differentiate the NMO-spectrum disease
patients from patients with multiple sclerosis. [15] In our small
series of four NMO patients and seventy-five multiple sclerosis
patients, however, we found low GFAP blood values in both
NMO- and multiple sclerosis patients not allowing for discrimi-
nation of both entities.
Regarding the potential application of GFAP as a biomarker of
acute ICH, it is of importance to set the results of the present study
into the context of the BE FAST trial, the largest study providing
data on diagnostic accuracy of GFAP for identifying ICH in
patients with symptoms of acute stroke so far. [4] In acute ICH
patients, even at very early time points, GFAP plasma values as
high as 100 mg/l were found, resulting from the immediate
destruction of astroglial cells by the expanding hematoma. In
contrast, in case of IS, GFAP release occurs in a more delayed
manner, following the delayed dynamics of necrosis and cytolysis.
[1] Among more than 160 patients with IS, only a few were found
with (slightly) increased plasma concentrations, but still below
1 mg/l. 0.29 mg/l emerged as an optimal cut point to differentiate
between ICH and IS. [4] Regarding potential ‘‘specificity gaps’’ of
a future GFAP test applied to identify ICH, we may first consider
typical ‘‘stroke mimicking’’ conditions. According to our study,
typical stroke mimics such as migraine and epilepsy should not
lead to false positive testing. However, a malignant brain tumor –
which may sporadically present as a stroke mimic - may be falsely
identified as an ICH. If the medical history of the patient is
suggestive of a rather chronic than acute disease, the results of the
test may be considered with caution. Difficulties may also occur if
a patient with IS suffers from traumatic brain injury, e.g. as
a consequence of a fall at symptom onset. In order to avoid false
positive results, patients with an apparent trauma may not be
tested. Most patients with subarachnoid hemorrhage do not
present with a typical stroke syndrome. However, patients with
parenchymal involvement may demonstrate focal neurological
deficits, but are then likely to present with increased GFAP values,
and will be correctly classified as ‘‘ICH’’. All other diseases that
may sporadically lead to increased GFAP values, e.g. severe
bacterial meningitis, can hardly be considered as a relevant ‘‘stroke
mimic’’.
Taken together, GFAP is an attractive candidate protein that
fulfills many of the criteria commonly asked for an ‘‘ideal’’
biomarker. It is abundantly present in the target organ, highly
brain specific, biochemically stable and robust, and its plasma
values are directly related to the extent of brain damage if used as
an indicator of ICH. In this study, we were able to show, that age,
sex, co-morbidities, risk factors as well as the vast majority of
neurological diseases, especially the classical ‘‘stroke mimics’’ do
not critically interfere with the use of GFAP as an ICH biomarker.
Thus, bearing the above-mentioned limitations in mind, GFAP
might be highly valid and reliable in indicating acute ICH in
patients with symptoms suspicious of acute stroke.
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